Improvements were seen in some patients participating in a phase 3 clinical trial as quickly as 4 weeks after the first treatment.
Rita Baron-Faust, MPH
New guidelines issued at EULAR 2015 outline ways to reduce risks of complications for pregnant women with SLE and antiphospholipid syndrome. Details here.
Only 1% to 3% of patients with non-radiographic axial spondyloarthritis achieve remission or low disease activity without TNF-α blockers, but these agents are not yet approved for this use in the US.